[The treatment of metastasising mammary carcinoma with drostanolone propionate (masterid) (author's transl)].
D000328:Adult; D000367:Age Factors; D000368:Aged; D000732:Androstanols / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D010053:Ovary / Q000528:radiation effects; D012075:Remission, Spontaneous; D014770:Virilism / Q000139:chemically induced
D000732:Androstanols; D000970:Antineoplastic Agents
Die Behandlung des metastasierenden Mammakarzinoms mit Drostanolon-Propionat (Masterid)